Literature DB >> 12771962

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.

Yong Zhang1, Xinsheng Gao, Leslie J Saucedo, Binggen Ru, Bruce A Edgar, Duojia Pan.   

Abstract

Mutations in the TSC1 or TSC2 genes cause tuberous sclerosis, a benign tumour syndrome in humans. Tsc2 possesses a domain that shares homology with the GTPase-activating protein (GAP) domain of Rap1-GAP, suggesting that a GTPase might be the physiological target of Tsc2. Here we show that the small GTPase Rheb (Ras homologue enriched in brain) is a direct target of Tsc2 GAP activity both in vivo and in vitro. Point mutations in the GAP domain of Tsc2 disrupted its ability to regulate Rheb without affecting the ability of Tsc2 to form a complex with Tsc1. Our studies identify Rheb as a molecular target of the TSC tumour suppressors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771962     DOI: 10.1038/ncb999

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  369 in total

1.  Regulation of mTORC1 by the Rab and Arf GTPases.

Authors:  Li Li; Eunjung Kim; Haixin Yuan; Ken Inoki; Pankuri Goraksha-Hicks; Rachel L Schiesher; Thomas P Neufeld; Kun-Liang Guan
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

2.  Size matters. Workshop on growth control in development and disease.

Authors:  Duojia Pan
Journal:  EMBO Rep       Date:  2004-01-23       Impact factor: 8.807

Review 3.  Deconvoluting mTOR biology.

Authors:  Jason D Weber; David H Gutmann
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

Review 4.  Translational regulation in nutrigenomics.

Authors:  Botao Liu; Shu-Bing Qian
Journal:  Adv Nutr       Date:  2011-11-03       Impact factor: 8.701

5.  Differential transcriptomic analysis of spontaneous lung tumors in B6C3F1 mice: comparison to human non-small cell lung cancer.

Authors:  Arun R Pandiri; Robert C Sills; Vincent Ziglioli; Thai-Vu T Ton; Hue-Hua L Hong; Stephanie A Lahousse; Kevin E Gerrish; Scott S Auerbach; Keith R Shockley; Pierre R Bushel; Shyamal D Peddada; Mark J Hoenerhoff
Journal:  Toxicol Pathol       Date:  2012-06-11       Impact factor: 1.902

Review 6.  mTOR signaling in cancer cell motility and tumor metastasis.

Authors:  Hongyu Zhou; Shile Huang
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2010       Impact factor: 1.807

7.  Curcumin disrupts the Mammalian target of rapamycin-raptor complex.

Authors:  Christopher S Beevers; Long Chen; Lei Liu; Yan Luo; Nicholas J G Webster; Shile Huang
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 8.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

9.  The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.

Authors:  T R Hartman; E Nicolas; A Klein-Szanto; T Al-Saleem; T P Cash; M C Simon; E P Henske
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

10.  Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development.

Authors:  Yann-Gaël Gangloff; Matthias Mueller; Stephen G Dann; Petr Svoboda; Melanie Sticker; Jean-Francois Spetz; Sung Hee Um; Eric J Brown; Silvia Cereghini; George Thomas; Sara C Kozma
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.